BREAKING NEWS

LabCorp Exclusively Launches Sera Prognostics’ PreTRM Test to Assess for Risk of Preterm Birth

Clinical Innovation

Landmark PAPR Published Online in American Journal of Obstetrics & Gynecology View Press Release

BREAKING NEWS

Two Peer-Reviewed Publications Highlight Clinical Utility of PreTRM® Test  Read More

PROTEOMIC INNOVATION

“We developed a novel blood test to PREDICT, at an EARLY point in pregnancy, a woman’s individual risk of having a premature baby. We aim to achieve our vision of improving the health of newborns by enabling earlier, effective interventions that make a difference.” Dr. Greg Critchfield, CEO

BREAKING NEWS

PreTRM Test Wins Silver at New York Edison Awards; Awards Celebrate 30 Years of Honoring Innovators and Innovation Read More

News

Key Strategies for Implementing Proteomics-Based Tests Across Disease States Highlighted in Current Opinion in Biotechnology

Seattle, WA and Salt Lake City, February 12 - Sera Prognostics, in collaboration with The Institute for Systems Biology and Integrated Diagnostics (Indi), today announced a paper entitled, "The building blocks of successful translation of proteomics to the clinic," by Leroy Hood and colleagues published online in Current Opinion in Biotechnology. Read More >

LabCorp Exclusively Launches Sera Prognostics’ PreTRM Test to Assess for Risk of Preterm Birth

BURLINGTON, N.C. - May 23, 2017 - LabCorp® (NYSE: LH) today announced the nationwide availability the PreTRM® test. Developed by Sera Prognostics, Inc., the PreTRM test is the first of its kind validated blood test that provides an early and individualized prediction of preterm birth risk for pregnant women. LabCorp and Sera previously announced their strategic collaboration for LabCorp to be the exclusive U.S. distributor of Sera’s PreTRM test. LabCorp was also a lead investor in Sera’s recently closed Series C financing round. Read More >

Sera Prognostics Appoints Nadia Altomare as Chief Commercial Officer

SALT LAKE CITY, May 17, 2017– Sera Prognostics announced today that Nadia F. Altomare has joined the company as chief commercial officer. Ms. Altomare will lead all commercial activities for Sera as the company makes its groundbreaking PreTRM® test available to physicians and patients. The PreTRM test is the first and only broadly clinically-validated blood test that provides an early and individualized prediction of preterm birth risk. Read More >

Awards

Our Goals

Providing An Individualized Risk Assessment to Predict and Manage premature birth, preeclampsia, and other Pregnancy Complications

Sera Prognostics is focused on improving maternal and infant health by developing simple blood tests to predict the risks of pregnancy complications. Our initial focus is on one of the most serious pregnancy complications—preterm birth—which affects 9.6% of pregnancies in the U.S. alone.

Early and accurate prediction of risk for pregnancy complications may help pregnant women and their doctors take action and make a difference by putting early interventions in place. Learn about the PreTRM® Test for Risk Management.